Sentence examples for most common adjuvant from inspiring English sources
Currently, the most common adjuvant used in experimental animals is Freund's adjuvants, which can enhance strong antigen-specific immune responses.
For example, the most common adjuvant, aluminum salt (alum), lacks the ability to induce cell-mediated immunity, which is considered protective in cases of intracellular pathogen-derived diseases or cancer 23.
Next to radiation therapy, endocrine hormonal treatments, primarily tamoxifen (TAM) and aromatase inhibitors (AIs), are the most common adjuvant treatment for women with hormone receptor-positive breast cancer [ 3– 7].
The most common adjuvant medications used by the clients were: the anticholinergic/antiparkinsonian drug, trihexyphenidyl (177; 71.1%) followed by antidepressants (29; 11.7%) and mood stabilizers (26; 10.4%) and benzodiazepines (anxiolytics) (17; 6.8%).
The failure of some breast cancers to respond to tamoxifen, currently the most common adjuvant endocrine treatment, is a major clinical problem and several resistance mechanisms have been elucidated [ 1, 2].
The majority of patients in each cohort received adjuvant treatment: 47 % in cohort A and 77 % in cohort C. Overall, hormone therapy was the most common adjuvant therapy across cohorts (79% and 933 %, respectively).
Tramadol and ketamine are the most common adjuvants used with local anesthetics [ 6, 7].
In this article, we briefly review the challenges associated with most common mucosal adjuvants and discuss potential strategies for targeting the mucosal immune system.
Furthermore, one of the most common vaccine adjuvants, alum, acts by stimulating the release of DNA from neutrophils (Zhang et al., 2011b).
On the other hand, the most common regimen for adjuvant chemotherapy for pathological stage II or III NSCLC is VNR+CDDP, because most randomised trials, which resulted in positive results, adopted VNR+CDDP.
Platinum, combined with cyclophosphamide- or taxane-based chemotherapy, is the most common cytotoxic regimen for adjuvant chemotherapy of EOC patients (Rustin et al, 1996).
